ATT as per Latest NTEP Guidelines
India's National Tuberculosis Elimination Programme (NTEP) currently recommends a daily fixed-dose combination (FDC) regimen for drug-susceptible tuberculosis, consisting of 2 months intensive phase with Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), and Ethambutol (E) followed by 4 months continuation phase with Isoniazid and Rifampicin—a total of 6 months treatment 1, 2.
Standard Drug-Susceptible TB Regimen
The NTEP has transitioned from the previous thrice-weekly DOTS regimen to a daily dosing schedule using 4-drug fixed-dose combinations 2, 3. This represents a significant programmatic shift aimed at improving treatment outcomes.
Intensive Phase (2 months):
- Daily administration of H+R+Z+E as fixed-dose combination
- All four drugs given together once daily
- Duration: 56 doses over 8 weeks
Continuation Phase (4 months):
- Daily administration of H+R as fixed-dose combination
- Two drugs given together once daily
- Duration: 120 doses over 16 weeks
Total Treatment Duration: 6 months (182 doses)
Weight-Based Dosing
While the provided evidence doesn't specify exact NTEP dosing, standard international guidelines that inform NTEP protocols recommend:
- Isoniazid: 5 mg/kg (max 300 mg daily)
- Rifampicin: 10 mg/kg (<50 kg: 450 mg; ≥50 kg: 600 mg)
- Pyrazinamide: 25-35 mg/kg (<50 kg: 1.5 g; ≥50 kg: 2.0 g)
- Ethambutol: 15-20 mg/kg
Key Programmatic Changes
Shift from Supervised to Self-Administered Therapy
Critical caveat: Unlike the previous DOTS regimen where drug intake was directly observed, the current daily regimen relies primarily on patient self-administration 3. This represents both an advantage (daily dosing improves pharmacokinetics) and a significant challenge (adherence monitoring is more difficult).
Research shows that only 53.4% of patients demonstrate true adherence when objectively measured by urine drug metabolite testing, despite 63.7% self-reporting adherence 3. This discrepancy highlights a major implementation gap.
Common Reasons for Non-Adherence:
- Side effects of anti-tubercular drugs (18.6%)
- Loss of daily wages (15.0%)
- Forgetfulness (10.0%)
Special Situations
TB Meningitis/CNS Disease:
- Same 4-drug intensive phase for 2 months
- Extended continuation phase to 10 months (total 12 months)
- Consider corticosteroids for severe disease
Extrapulmonary TB:
- Standard 6-month regimen for most sites (lymph nodes, bone/joint, genitourinary)
- Exception: CNS involvement requires 12 months
Children:
- Same regimen structure as adults
- Weight-based dosing adjusted appropriately
- Ethambutol can be used safely at 15 mg/kg even in young children
Drug-Resistant TB
For MDR/RR-TB (multidrug-resistant/rifampicin-resistant), NTEP follows WHO guidelines recommending:
Shorter All-Oral Regimen (9-12 months):
Eligible patients receive bedaquiline-containing regimen:
- Intensive phase (4-6 months): Bedaquiline + Levofloxacin/Moxifloxacin + Clofazimine + Pyrazinamide + Ethambutol + High-dose Isoniazid + Ethionamide
- Continuation phase (5 months): Levofloxacin/Moxifloxacin + Clofazimine + Pyrazinamide + Ethambutol 4
Eligibility Criteria:
- No previous second-line drug exposure >1 month
- No fluoroquinolone resistance
- No extensive pulmonary disease or severe extrapulmonary TB
- Not pregnant
- Age >6 years
Longer Individualized Regimen (18-24 months):
Required for patients with:
- Extensive pulmonary disease
- Fluoroquinolone resistance
- Previous second-line drug exposure
- Severe extrapulmonary TB
Critical Implementation Considerations
Monitoring Adherence:
Given the 46.6% non-adherence rate 3, urine drug metabolite testing using HPLC should be considered for high-risk patients, as patient self-reporting is unreliable.
Pharmacokinetic Concerns:
Studies show 60% of patients have suboptimal rifampicin levels and 25% have suboptimal isoniazid levels with current FDC formulations 2. However, adequate pyrazinamide levels may compensate, as all patients in the study achieved cure despite suboptimal H and R concentrations.
Patient Education Requirements:
With daily self-administered therapy, comprehensive patient counseling about:
- Disease transmission and infectiousness
- Importance of completing full 6-month course
- Recognition of side effects
- When to seek medical attention
Pyridoxine Supplementation:
Vitamin B6 (25-50 mg daily) should be given to patients at risk of peripheral neuropathy:
- Pregnant/breastfeeding women
- HIV-positive patients
- Diabetics
- Alcoholics
- Malnourished patients
- Elderly patients
Bacteriological Confirmation
All patients should have bacteriological confirmation and drug susceptibility testing whenever possible to guide appropriate treatment and detect drug resistance early 5.
Follow-up Monitoring:
- Sputum examination at 2,4, and 6 months
- If culture-positive at 2 months with cavitary disease, consider extending continuation phase to 7 months
- Chest X-ray at completion of treatment
Notification and Case Management
All TB cases must be promptly notified to local health authorities for contact tracing, adherence monitoring, and surveillance 6, 7.
The shift to daily self-administered therapy under NTEP requires robust case management systems including patient reminders, home visits, and integration with primary care to overcome the adherence challenges documented in recent Indian studies 3.